Mohammed A. Elbahloul: Every Minute Counts in STEMI Revascularization
Mohammed A. Elbahloul, Guest Editor at Plos One, shared a post on LinkedIn about a recent article he and her colleagues co-authored, published in Cardiovascular Interventions logo Journal, adding:
”I’m pleased to share that our manuscript, ‘Timing of Complete Revascularization in Patients With STEMI and Multivessel Disease: An Updated Meta-Analysis of Randomized Clinical Trials,’ has been published in Circulation: Cardiovascular Interventions (IF: 7.4).
I would like to express my sincere gratitude to my co-authors and mentors for their invaluable contributions and support throughout this work.
Key Findings:
- Primary Outcome: In hemodynamically stable patients with STEMI and multivessel disease, an immediate complete revascularization (ICR) strategy may be associated with an increased risk of short-term cardiac death compared with staged complete revascularization (SCR).
- Mortality Trends: Based on the current evidence, a potential increase in both early and late all-cause mortality with ICR cannot be excluded.
- Secondary Endpoints: No significant differences were observed between ICR and SCR in myocardial infarction, repeat revascularization, stent thrombosis, stroke, or major bleeding.
- Clinical Implications: While some uncertainty remains, these findings support a staged complete revascularization strategy for most patients with STEMI and multivessel disease.”
Title: Timing of Complete Revascularization in Patients With STEMI and Multivessel Disease: An Updated Meta-Analysis of Randomized Clinical Trials
Authors: Mohammed A. Elbahloul, Shrouk Ramadan, Eman E. Labeeb, Shahed Aldalahmeh, Ahella Ismail A. Mousa, Ahmed Elazab, Ahmed N. Mohamed, Ahmad Elashery, Mehiar O. El-Hamdani, Carl J. Lavie, Gregg W. Stone
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering